Literature DB >> 19828010

Molecular changes in pancreatic cancer.

Malte Buchholz1, Thomas M Gress.   

Abstract

As with many human malignancies, pancreatic cancer is a complex genetic disorder. Several thousand disease-associated alterations on the DNA, mRNA, miRNA and protein levels have been reported to date. Some of these alterations, including a number of gatekeeper mutations, which are of pre-eminent importance for the onset and progression of the disease, have been extensively studied in primary tissues, in vitro experiments and transgenic mouse models. For the vast majority of alterations, however, data about the functional significance are lacking. The situation is complicated by the fact that no certainty exists concerning the identity of the cells that originally undergo malignant transformation nor about the precise nature and fate of premalignant lesions that are observed in pancreatic tissues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828010     DOI: 10.1586/era.09.107

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  11 in total

Review 1.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

2.  Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer.

Authors:  Yue Zhao; Lu Zhao; Ivan Ischenko; Qi Bao; Bettina Schwarz; Hanno Nieß; Yan Wang; Andrea Renner; Josef Mysliwietz; Karl-Walter Jauch; Peter J Nelson; Joachim W Ellwart; Christiane J Bruns; Peter Camaj
Journal:  Target Oncol       Date:  2015-02-03       Impact factor: 4.493

3.  Emerging therapies in pancreas cancer.

Authors:  Adam Kotowski; Wen W Ma
Journal:  J Gastrointest Oncol       Date:  2011-06

4.  A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).

Authors:  Eileen M O'Reilly; Donna Niedzwiecki; Margaret Hall; Donna Hollis; Tanios Bekaii-Saab; Timothy Pluard; Kathe Douglas; Ghassan K Abou-Alfa; Hedy L Kindler; Richard L Schilsky; Richard M Goldberg
Journal:  Oncologist       Date:  2010-12-10

Review 5.  Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival.

Authors:  Mark B Ulanja; Alastair E Moody; Bryce D Beutler; Daniel Antwi-Amoabeng; Ganiyu A Rahman; Olatunji B Alese
Journal:  Oncotarget       Date:  2022-06-15

6.  Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.

Authors:  Jan N Kreutzer; Maria Ruzzene; Barbara Guerra
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

7.  2-Triazenoazaindoles: α novel class of triazenes inducing transcriptional down-regulation of EGFR and HER-2 in human pancreatic cancer cells.

Authors:  Jan N Kreutzer; Alessia Salvador; Patrizia Diana; Girolamo Cirrincione; Daniela Vedaldi; David W Litchfield; Olaf-Georg Issinger; Barbara Guerra
Journal:  Int J Oncol       Date:  2011-11-29       Impact factor: 5.650

8.  Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Authors:  Darrell R Borger; Kenneth K Tanabe; Kenneth C Fan; Hector U Lopez; Valeria R Fantin; Kimberly S Straley; David P Schenkein; Aram F Hezel; Marek Ancukiewicz; Hannah M Liebman; Eunice L Kwak; Jeffrey W Clark; David P Ryan; Vikram Deshpande; Dora Dias-Santagata; Leif W Ellisen; Andrew X Zhu; A John Iafrate
Journal:  Oncologist       Date:  2011-12-16       Impact factor: 5.837

9.  Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells.

Authors:  B P Kaistha; T Honstein; V Müller; S Bielak; M Sauer; R Kreider; M Fassan; A Scarpa; C Schmees; H Volkmer; T M Gress; M Buchholz
Journal:  Br J Cancer       Date:  2014-08-19       Impact factor: 7.640

10.  Composition and cytotoxic activity of essential oils from Xylopia aethiopica (Dunal) A. Rich, Xylopia parviflora (A. Rich) Benth.) and Monodora myristica (Gaertn) growing in Chad and Cameroon.

Authors:  Issakou Bakarnga-Via; Jean Baptiste Hzounda; Patrick Valere Tsouh Fokou; Lauve Rachel Yamthe Tchokouaha; Magali Gary-Bobo; Audrey Gallud; Marcel Garcia; Lucain Walbadet; Youssouf Secka; Pierre Michel Jazet Dongmo; Fabrice Fekam Boyom; Chantal Menut
Journal:  BMC Complement Altern Med       Date:  2014-04-04       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.